KTTA Stock Analysis
KT
Uncovered
Pasithea Therapeutics Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 3 full-time employees. The company went IPO on 2021-08-13. The firm is engaged on psychiatric and neurological research regarding central nervous system (CNS) disorders with focus on translating the research into clinic-ready drugs. The firm's secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician or medical providers to administer intravenous infusions of ketamine.